Search clinical trials for: Eltrombopag olamine

Total 5013 results

Fondazione Progetto Ematologia

Completed

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Chronic Lymphocytic Leukemia | Purpura, Thrombocytopenic, Idiopathic | Non Hodgkin's Lymphoma | Autoimmune Thrombocytopenia | Autoimmune Thrombocytopenic Purpura

Italy
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
National Taiwan University Hospital
Novartis

Recruiting

Eltrombopag for Peripheral Blood Stem Cell Harvest (EPBSCH)

Lymphoma | Peripheral Blood Stem Cell Transplantation

Taiwan
GlaxoSmithKline

Completed

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Myelodysplastic Syndrome

Puerto Rico, United States, Taiwan, Germany, Denmark, Hong Kong, Korea, Republic of, France, United Kingdom, Italy, Brazil
Tongji Hospital

Not yet recruiting

Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

Myelodysplastic Syndromes
RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia (H-CIT-AML)

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Immune Thrombocytopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Purpura, Thrombocytopenic, Idiopathic

China
Huazhong University of Science and Technology

Recruiting

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy (hetrombopag)

Malignant Tumors of the Digestive System | Trombocitopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Extension Study of Hetrombopag in Severe Aplastic Anemia

Treatment-naive Severe Aplastic Anemia

China
Case Comprehensive Cancer Center

Active, not recruiting

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Idiopathic Thrombocytopenic Purpura

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

Healthy

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Hematopoietic Cell Transplantation Recipient | Bone Marrow Transplantation Recipient | Cord Blood Transplant Recipient

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Severe Aplastic Anemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Primary Myelofibrosis | Thrombocytopenia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Thrombocytopaenia

United States, Germany, Israel, Belgium, Finland, Ireland, Italy, Greece, India, Czech Republic, Hungary, Canada, Poland
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

Russian Federation
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
Weill Medical College of Cornell University
Novartis

Terminated

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
Tel-Aviv Sourasky Medical Center
Novartis

Recruiting

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

B Cell Lymphoma | CART Treatment

Israel
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

Primacy Immune Thrombocytopenia

Italy
Novartis Pharmaceuticals

Completed

Drug Use Investigation for REVOLADE (ITP)

Purpura, Thrombocytopaenic, Idiopathic
Assiut University

Unknown

Eltrombopag in Chronic ITP

Immune Thrombocytopenia
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaborators

Unknown

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

Acute Myeloid Leukemia | Thrombocytopenia | Eltrombopag

China
IRCCS Policlinico S. Matteo

Completed

Eltrombopag for Inherited Thrombocytopenias

Inherited Platelet Disorder

Italy
Dana-Farber Cancer Institute

Terminated

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Multiple Myeloma | Thrombocytopenia

United States
GlaxoSmithKline

Completed

WEUSKOP5410: Observational Study in ENABLE Clinical Trials

Hepatitis C
GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
University Hospital, Lille

Recruiting

RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation (REGALIA)

Leukemia | Graft Failure

France
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function (ELTION)

Poor Graft Function

Spain
GlaxoSmithKline

Completed

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States
GlaxoSmithKline

Completed

A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

Cirrhosis, Liver

Mexico
University of Utah
Novartis

Completed

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

Severe Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic Anemia

United States
Jane Liesveld

Completed

Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

Thrombocytopenia | Acute Radiation Syndrome
GlaxoSmithKline

Withdrawn

Milk-only Lactation Study for Patients on Eltrombopag

Thrombocytopaenia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Completed

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Leukemia | CLL

United States
Groupe Francophone des Myelodysplasies
GlaxoSmithKline; Novartis

Completed

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Thrombocytopenia | CMML

France
GlaxoSmithKline

Completed

Meta-analysis - Eltrombopag

Thrombocytopaenia
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
moshe yeshurun
GlaxoSmithKline

Unknown

Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.

Israel

Search clinical trials for: Eltrombopag olamine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations